The Comprehensive Clinical Trials Unit at UCL


Publication: EXENATIDE-PD3

12 May 2021

Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson’s disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The ‘Exenatide-PD3’ study

The EXENATIDE-PD3 trial team have published a paper in the BMJ Open journal, which is available to read on the BMJ Open website here.